BRAF and Langerhans cell histiocytosis: A multicenter clinical study in France involving 366 pediatric LCH found no significant differences in disease characteristics and outcomes between the subgroup with MAP2K1 mutations (n = 44) and that with BRAF exon 12 mutation (n = 34).